Maine backs 25% Rx discounts for poor

10 May 2001

In the US state of Maine, the legislature's Health and Human ServicesCommittee has voted unanimously in favor of proposals to provide prescription drug discounts averaging 25% for around 225,000 elderly and disabled people in the state whose incomes are up to 300% of the federal poverty level and who have no other drug coverage.

The bipartisan committee approved the bill to enact the Healthy Maine Prescription Program, which is based on Vermont's Pharmacy Discount Program. This went live in January (Marketletter January 15), despite a court challenge from the Pharmaceutical Research and Manufacturers of America which attempted to block the Health Care Financing Administration waiver required for setting up the program.

An HCFA waiver for the establishment of the Healthy Maine Prescription Program was secured in January, and the plan is now expected to pass the full state legislature and then be signed into law by the Governor, Angus King, after which it would take effect immediately, reports Reuters.

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK





Today's issue

Company Spotlight